ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)	6 Months Ended
	Jun. 30, 2012
ORGANIZATION AND DESCRIPTION OF BUSINESS [Abstract]
Number of European countries where XIAFLEX is selling	9
Number of dogs on which single injection study evaluate	32
Ratio of XIAFLEX to placebo	1
Number of randomized, double-blind, placebo-controlled studies of IMPRESS Phase III clinical program of XIAFLEX conducted by Auxilium	2
Period over which studies of IMPRESS Phase III clinical program of XIAFLEX were conducted by Auxilium (in weeks)	52
Number of U.S. patients diagnosed with human lipomas annually	575,000
Number of patients anticipated to participate in single center dose escalation study of Phase II trial of XIAFLEX for treatment of human lipoma	14
Subsequent Event [Member]
Subsequent Event [Line Items]
Subsequent event date	Jul. 30, 2012
Number of patients enrolled for open-label phase IIIb trial by Auxilium	60
Number of sites throughout U.S. and Australia at which patients were enrolled for open-label phase IIIb trial	8
Number of cords treated concurrently in Dupuytren's surgeries, minimum	2
Subsequent Event [Member] | Minimum [Member]
Subsequent Event [Line Items]
Percentage of annual Dupuytren's surgeries in the US performed to treat two or more cords concurrently (in hundredths)	35.00%
Subsequent Event [Member] | Maximum [Member]
Subsequent Event [Line Items]
Percentage of annual Dupuytren's surgeries in the US performed to treat two or more cords concurrently (in hundredths)	40.00%